Update on the epidemiology and management of cryptococcal meningitis

Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis

(2011) A. Loyse et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of a Newly Developed Lateral Flow Immunoassay for the Diagnosis of Cryptococcosis

(2011) M. D. Lindsley et al.   CLINICAL INFECTIOUS DISEASES

Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure

(2011) Ishan Wijewardana et al.   JOURNAL OF INFECTION

Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection

(2011) Yi-Chien Lee et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals

(2011) Edmond J. Byrnes et al.   MICROBES AND INFECTION

Evaluation of Cryptococcus neoformans galactoxylomannan–protein conjugate as vaccine candidate against murine cryptococcosis

(2011) Siu-Kei Chow et al.   VACCINE

Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule ofCryptococcus neoformans

(2011) Magdia De Jesus et al.   Virulence

The effect of L-DOPA onCryptococcus neoformansgrowth and gene expression

(2011) Helene C. Eisenman et al.   Virulence

The Outbreak of Cryptococcus gattii in Western North America: Epidemiology and Clinical Issues

(2011) Edmond J. Byrnes et al.   Current Infectious Disease Reports

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Emergence and Pathogenicity of Highly Virulent Cryptococcus gattii Genotypes in the Northwest United States

(2010) Edmond J. Byrnes et al.   PLoS Pathogens

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

(2009) Benjamin J Park et al.   AIDS

Lipid Formulations of Amphotericin B Significantly Improve Outcome in Solid Organ Transplant Recipients with Central Nervous System Cryptococcosis

(2009) Hsin‐Yun Sun et al.   CLINICAL INFECTIOUS DISEASES

Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study

(2009) Somnuek Sungkanuparph et al.   CLINICAL INFECTIOUS DISEASES

Combination Flucytosine and High‐Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi

(2009) Jesse C. Nussbaum et al.   CLINICAL INFECTIOUS DISEASES

Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36

(2009) Terry K. Means et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation

(2009) H. Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systematic Genetic Analysis of Virulence in the Human Fungal Pathogen Cryptococcus neoformans

(2008) Oliver W. Liu et al.   CELL

Epidemiology and management of cryptococcal meningitis: developments and challenges

(2008) Read Pukkila-Worley et al.   EXPERT OPINION ON PHARMACOTHERAPY